









Markets
/
Stocks
/
nasdaq-amgn
/

Amgen Inc

AMGN



View Detailed Chart

291.590USD

-0.180-0.06%

Market hours （ET）Quotes delayed by 15 min

156.96BMarket Cap

23.71P/E TTM



Amgen Inc

291.590

-0.180-0.06%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-0.06%

5 Days

-1.48%

1 Month

+6.43%

6 Months

+1.05%

Year to Date

+11.87%

1 Year

-7.72%

View Detailed Chart

TradingKey Stock Score of Amgen Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Amgen Inc's Score

Industry at a Glance

Industry Ranking

44 / 160

Overall Ranking

118 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 34 analysts

Buy

Current Rating

313.364

Target Price

+7.28%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Amgen Inc Highlights

StrengthsRisks

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.98% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.

Fairly Valued

The company’s latest PE is 23.69, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 452.81M shares, decreasing 0.58% quarter-over-quarter.

Held by Bill Smead

Star Investor Bill Smead holds 922.97K shares of this stock.

News

Bernstein cuts Amgen PT on uncertainty over obesity drug candidate MariTide

** Bernstein cuts PT on drugmaker Amgen AMGN.O to $350 from $380, citing uncertainty over co's key obesity drug candidate MariTide** New PT is nearly a 19% upside to stock's last close** Brokerage says MariTide is a higher-risk-and-high-reward opportunity** Adds obesity pipeline is advancing...

ReutersThu, Feb 20

Amgen profits rise, next MariTide studies start by mid-year

Feb 4 (Reuters) - Amgen AMGN.O posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.

ReutersTue, Feb 4